Phase 3 Pancreatic cancer trials recruiting now

All Pancreatic cancer trials, every phase

Other phases for Pancreatic cancer

Phase 3 Pancreatic cancer trials

• 18F-DOPA II - PET Imaging Optimization
  NCT04706910 · Phase: Phase 3 · Ages: No age limits stated · Sex: All (male and female) · 1 location
• A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)
  NCT07066098 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
  NCT06881992 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
  NCT03394365 · Phase: Phase 3 · Ages: No age limits stated · Sex: All (male and female) · 71 locations
• A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
  NCT06361888 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
  NCT06953999 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
  NCT06079346 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer
  NCT07079228 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
  NCT07522073 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 219 locations
• A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
  NCT07409272 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 62 locations
• A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
  NCT06989437 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 220 locations
• Adjuvant Chemoradiotherapy Versus Chemotherapy for Pancreatic Cancer (ADJUPANC)
  NCT06427447 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
  NCT05884255 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
  NCT07562152 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 41 locations
• Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Gemcitabine Combined With Paclitaxel Protein-bound
  NCT07716228 · Phase: Phase 3 · Ages: 18 Years to 85 Years · Sex: All (male and female) · 1 location
• Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
  NCT07087054 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 67 locations
• Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency
  NCT06095141 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer
  NCT05653453 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 5 locations
• DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
  NCT05786716 · Phase: Phase 2, Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · 27 locations
• DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
  NCT07440290 · Phase: Phase 2, Phase 3 · Ages: 1 Year and older · Sex: All (male and female) · 27 locations
• Evaluating Novel Therapies in ctDNA Positive GI Cancers
  NCT05482516 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial
  NCT06593431 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer
  NCT07235930 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.
  NCT06897644 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 28 locations
• Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
  NCT01954992 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer
  NCT07232875 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial
  NCT05744219 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
  NCT03257033 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 42 locations
• Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer
  NCT07238283 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy?
  NCT05720338 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
  NCT06807437 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 118 locations
• Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery
  NCT06391892 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 1 location
• Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
  NCT06782412 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP
  NCT05268692 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 85 Years · Sex: All (male and female) · 1 location
• Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer
  NCT07081360 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Pancreatic Cancer Diagnosis With FAPI-PET Imaging
  NCT07098598 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 85 Years · Sex: All (male and female) · 1 location
• Pancreatic Head Resection or Total Pancreatectomy With Islet Autotransplantation in Patients With Periampullary Cancer and High Risk Profile for the Development of Postoperative Pancreatic Fistula
  NCT05843877 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer
  NCT07262567 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer
  NCT06752811 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery
  NCT07632118 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer
  NCT06250972 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX
  NCT07044453 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer
  NCT04969731 · Phase: Phase 3 · Ages: 19 Years to 80 Years · Sex: All (male and female) · 1 location
• Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC
  NCT06714604 · Phase: Phase 3 · Ages: 18 Years to 90 Years · Sex: All (male and female) · 1 location
• Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
  NCT07252232 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 66 locations
• Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
  NCT07491445 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 33 locations
• Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
  NCT05254171 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 93 locations
• Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
  NCT05477576 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 54 locations
• Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
  NCT07621718 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
  NCT07219238 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
  NCT06998940 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 274 locations
• Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer
  NCT07436741 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
  NCT06958328 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 322 locations
• Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer
  NCT06017284 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• The Cancer of the Pancreas Screening-5 CAPS5)Study
  NCT02000089 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
  NCT06861088 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas
  NCT07155525 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
  NCT03755739 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Vitamin C Plus Cordyceps to Chemotherapy Related Anemia in Pancreatic Cancer
  NCT06601283 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Vitamin C Plus Cordyceps to Quality of Life in Patients With Terminal Stage Pancreatic Cancer
  NCT06598033 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
  NCT06943755 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 124 locations
• tislelizUMaB in canceR Patients With molEcuLar residuaL Disease
  NCT06332274 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

What does Phase 3 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.